期刊
JOURNAL OF PROTEOME RESEARCH
卷 20, 期 7, 页码 3590-3599出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jproteome.1c00162
关键词
aggressive prostate cancer; urinary biomarkers; parallel reaction monitoring; glycoproteomics; mass spectrometry
资金
- National Institutes of Health, National Cancer Institute, Early Detection Research Network (EDRN) [U01CA152813]
- Patrick C. Walsh Prostate Cancer Research Fund (PCW) award
The study identified ACPP and CLU in urine, combined with PSA, as potential markers for aggressive prostate cancer detection. The developed PRM assays for urinary glycopeptides showed good repeatability and wide working range, improving discrimination power for aggressive PCa.Combining ACPP, CLU, and serum PSA into a three-signature panel further enhanced the predictive power towards aggressive PCa detection.
Recently, we have found that two urinary glycoproteins, prostatic acid phosphatase (ACPP) and clusterin (CLU), combined with serum prostate-specific antigen (PSA) can serve as a three-signature panel for detecting aggressive prostate cancer (PCa) based on a quantitative glycoproteomic study. To facilitate the translation of candidates into clinically applicable tests, robust and accurate targeted parallel reaction monitoring (PRM) assays that can be widely adopted in multiple labs were developed in this study. The developed PRM assays for the urinary glycopeptides, FLN*ESYK from ACPP and EDALN*ETR from CLU, demonstrated good repeatability and a sufficient working range covering three to four orders of magnitude, and their performance in differentiating aggressive PCa was assessed by the quantitative analysis of urine specimens collected from 69 nonaggressive (Gleason score = 6) and 73 aggressive (Gleason >= 8) PCa patients. When ACPP combined with CLU, the discrimination power was improved from an area under a curve (AUC) of 0.66 to 0.78. By combining ACPP, CLU, and serum PSA to form a three- signature panel, the AUC was further improved to 0.83 (sensitivity: 84.9%, specificity: 66.7%). Since the serum PSA test alone had an AUC of 0.68, our results demonstrated that the new urinary glycopeptide PRM assays can serve as an adjunct to the serum PSA test to achieve better predictive power toward aggressive PCa. In summary, our developed PRM assays for urinary glycopeptides were successfully applied to clinical PCa urine samples with a promising performance in aggressive PCa detection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据